Natera's Signatera test detects immunotherapy treatment response in new study
A new study demonstrates the ability of Natera's Signatera test to assess patient response to immunotherapy in the metastatic setting across multiple cancer types by detecting molecular traces of circulating tumor DNA in the blood. The study was presented at the American Society of Clinical Oncology Annual Meeting in Chicago on June 1. The study, conducted by Princess Margaret Cancer Centre in Toronto, enrolled 70 patients with advanced cancer, including head and neck, triple-negative breast, melanoma, and ovarian cancers. Patients were treated with the single-agent immune checkpoint inhibitor pembrolizumab as part of the phase II INSPIRE trial. The study used Signatera to assess ctDNA at baseline and again at the start of the third treatment cycle. Results showed a strong correlation between changes in ctDNA and overall survival, progression-free survival, and overall clinical response rate, illustrating that ctDNA may be a valuable predictive biomarker for patients with mixed solid tumors treated with checkpoint inhibitors. Signatera, a personalized, tumor-informed blood test, detected ctDNA in 68 out of 70 patients at baseline (97% sensitivity).